{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:14:49Z","timestamp":1761804889537,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofcardiologycases.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology Cases"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jccase.2022.12.009","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T07:58:35Z","timestamp":1672991915000},"page":"176-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Initial clinical experience of intravenous tolvaptan sodium phosphate in patients with congestive heart failure"],"prefix":"10.1016","volume":"27","author":[{"given":"Makiko","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhiko","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Wakakuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Onoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Ushijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jccase.2022.12.009_bb0005","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","article-title":"JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure - digest version","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.jccase.2022.12.009_bb0010","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jccase.2022.12.009_bb0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11897-019-0424-1","article-title":"Diuretic resistance in heart failure","volume":"16","author":"Gupta","year":"2019","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jccase.2022.12.009_bb0020","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1253\/circj.CJ-19-0158","article-title":"Real-world effectiveness and tolerability of tolvaptan in patients with heart failure - final results of the samsca post-marketing surveillance in heart failure (SMILE) study","volume":"83","author":"Kinugawa","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.jccase.2022.12.009_bb0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ehf2.13111","article-title":"Temporal trends of a vasopressin V2 receptor antagonist in heart failure using a nationwide database in Japan","volume":"8","author":"Kuragaichi","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jccase.2022.12.009_bb0030","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1253\/circj.CJ-21-0430","article-title":"Pharmacokinetics, pharmacodynamics, efficacy, and safety of OPC-61815, a prodrug of tolvaptan for intravenous administration, in patients with congestive heart failure - a phase II, multicenter, double-blind, randomized, active-controlled trial","volume":"86","author":"Sato","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.jccase.2022.12.009_bb0035","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1002\/ehf2.14021","article-title":"Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure","volume":"9","author":"Sato","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jccase.2022.12.009_bb0040","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1253\/circj.CJ-21-0926","article-title":"Tolerability of the intravenously administered tolvaptan prodrug, OPC-61815, in patients with congestive heart failure who have difficulty with, or are incapable of, oral intake (TRITON-HF) - a phase III, multicenter, open-label trial","volume":"86","author":"Kinugawa","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.jccase.2022.12.009_bb0045","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1253\/circj.CJ-12-0971","article-title":"Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients\u2013association between non-responders and chronic kidney disease","volume":"77","author":"Imamura","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.jccase.2022.12.009_bb0050","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/ijms17010105","article-title":"Urine aquaporin-2: a promising marker of response to the arginine vasopressin type-2 antagonist, tolvaptan in patients with congestive heart failure","volume":"17","author":"Imamura","year":"2016","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Cardiology Cases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878540922002055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878540922002055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:12:55Z","timestamp":1761804775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878540922002055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1878540922002055"],"URL":"https:\/\/doi.org\/10.1016\/j.jccase.2022.12.009","relation":{},"ISSN":["1878-5409"],"issn-type":[{"type":"print","value":"1878-5409"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial clinical experience of intravenous tolvaptan sodium phosphate in patients with congestive heart failure","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology Cases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jccase.2022.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}